Mediators of Inflammation

Research Article

Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial

Table 4

Metabolic parameters at baseline (J0) and after 12 weeks (M3) of placebo or statin treatment.


	J0	M3	Change M3 − J0	Difference in change (95% CI)

Total cholesterol (g/L)
Placebo ()				−0.89 (−1.50; −0.27)
Statin ()	^$	^§	^£	−0.89 (−1.50; −0.27)
LDL cholesterol (g/L)
Placebo ()				−0.65 (−0.96; −0.34)
Statin ()				−0.65 (−0.96; −0.34)
HDL cholesterol (g/L)
Placebo ()				−0.31 (−0.78; 0.17)
Statin ()				−0.31 (−0.78; 0.17)
Triglycerides (g/L)
Placebo ()				0.09 (−0.27; 0.46)
Statin ()				0.09 (−0.27; 0.46)
Glycemia (mmol/L)
Placebo ()				0.06 (−0.34; 0.46)
Statin ()				0.06 (−0.34; 0.46)
Insulinemia (mUI/L)
Placebo ()				−2.27 (−8.96; 4.42)
Statin ()				−2.27 (−8.96; 4.42)
HOMA
Placebo ()				−0.66 (−2.83; 1.51)
Statin ()				−0.66 (−2.83; 1.51)
Hemoglobin A1c (%)
Placebo ()				0.04 (−0.12; 0.19)
Statin ()				0.04 (−0.12; 0.19)

Data are mean ± SD. LDL, low-density lipoprotein; HDL, high-density lipoprotein; HOMA, homeostasis model assessment of insulin resistance.
^$ for value group, ^§ value visit, ^£ value interaction, by repeated measure two-way ANOVA, followed by a Bonferroni post hoc test when necessary.